Kymera IPO Presentation Deck

IRAK4 Degradation In Vivo Active in Preclinical Mouse Gout Model IL-1R driven • Neutrophil recruitment and inflammasome dependent cytokine production measured upon activation with injected urate crystals in mouse + KT-474 blocked neutrophil infiltration and IL-18 production at doses and exposures resulting in 80% or greater IRAK4 reduction in the spleen Dose (mpk) BID Plasma [KT-474] µM KYMERA 0.87 Spleen [KT-474] µM 10.89 30 66% 100 80% 300 86% Inhibition of disease activity achieved with 80% degradation of IRAK4 in spleen 18 IRAK4 KD Percent 100 80 8 40 MSU Vehicle Neutrophils KT-474 30 mg/kg, PO BID ****p<0.0001 KT-474 100 mg/kg. PO BID KT-474 300 mg/kg, PO BID Total pg 500 400 200 100 IL-13 in Exudate MSU Vehicle KT-474 30 mg/kg, PO BID **p<0.001 KT-474 100 mg/kg. PO BID KT-474 300 mg/kg, PO BID

View entire presentation